One-Step Reverse-Transcription FRET-PCR for Differential Detection of Five *Ebolavirus* Species

Guangwu Lu¹, Jilei Zhang¹, Chuntao Zhang², Xiaolu Li³, Dawei Shi², Zhaopeng Yang², Chengming Wang¹*

¹ Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou University College of Veterinary Medicine, Yangzhou, Jiangsu, 225009, P. R. China, ² National Institute for Food and Drug Control (NIFDC), China Food and Drug Administration, Chongwen District, Beijing, 100050, P. R. China, ³ College of Chemistry, Chemical Engineering and Biotechnology, Donghua University, Shanghai, 201620, P. R. China

* wangcm@yzu.edu.cn

Abstract

Ebola is an emerging infectious disease caused by a deadly virus belonging to the family Filoviridae, genus *Ebolavirus*. Based on their geographical distribution, *Ebolavirus* has been classified into total five species so far, mainly Zaire, Sudan, Taï Forest, Bundibugyo and Reston. It is important to be able to differentiate the *Ebolavirus* species as they significantly differ in pathogenicity and more than one species can be present in an area. We have developed a one-step step-down RT-PCR detecting all five *Ebolavirus* species with high sensitivity (1 copy of *Ebolavirus* DNA, 10 copies of RNA and 320 copies of RNA spiked in 1 ml whole blood). The primers and FRET-probes we designed enabled us to differentiate five *Ebolavirus* species by distinct $T_m$ (Zaire: flat peaks between 53.0°C and 56.9°C; Sudan: 51.6°C; Reston: flat peaks between 47.5°C and 54.9°C; Taï Forest: 52.8°C; Bundibugyo: dual peaks at 48.9°C and 53.5°C), and by different amplicon sizes (Zaire 255bp, Sudan 211bp, Reston 192bp, Taï Forest 166bp, Bundibugyo 146bp). This one-size-fit-all assay enables the rapid detection and discrimination of the five *Ebolavirus* species in a single reaction.

Introduction

Ebola Virus Disease (EVD), previously known as Ebola hemorrhagic fever, is an emerging infectious disease caused by a deadly virus of the family Filoviridae, genus *Ebolavirus* [1, 2]. Of the five identified *Ebolavirus* species, four of them (*Zaire ebolavirus*, *Sudan ebolavirus*, *Taï Forest ebolavirus* and *Bundibugyo ebolavirus*) are known to cause disease in humans, whereas the fifth (*Reston ebolavirus*) causes disease in non-human primates and swine only [3–6]. Since human infections were first reported in 1976 on the Ebola River in Democratic Republic of the Congo [7], outbreaks of EVD have occurred into twelve countries (South Sudan, Democratic Republic of Congo, Côte d’Ivoire, Gabon, Uganda, Republic of Congo, Guinea, Philippines, Nigeria, Senegal, Liberia, Mali). There have also been imported cases in Sierra Leone, Spain, and...
the United States of America [8–10, 3, 11, 12]. By January 25, 2015, a total of 22,092 cases of Ebola infections have been confirmed, of which 8,810 cases of EVD have been fatal [12].

While simple or multiplex PCRs have been successfully used to detect Ebola virus, most of the published assays can only detect a single Ebola virus species [13, 14] or, in the case of those that detect multiple Ebola virus species, they show reduced sensitivity [15–17]. Whereas simple PCR tends to provide high sensitivity but lacks the ability to differentiate multiple targets simultaneously [13, 14, 18], multiplex PCR has the capacity to detect and differentiate multiple targets but tends to have a reduced sensitivity [17, 19–21]. The TaqMan RT-PCR assay targeting the nucleoprotein gene of Zaire ebolavirus developed by Huang Y et al. [14] had a wide range in sensitivity, from $10^3$ to $10^9$ virus copies per reaction. The primers and fluorogenic probe of the one-step qRT-PCR described by Towner JS et al. [13] were specific for Sudan ebolavirus and showed a high sensitivity ($10^4$ genomic-sense Ebola virus-RNA copies per ml; one genomic-sense RNA per reaction). Panning et al. [19] established a complicated system with 3 primers and 3 probes for Filoviridae with the detection limit from 487 to 4546 RNA copies/ml depending on the species of Ebola virus. Trombley et al. [20] established a system to detect multiple hemorrhagic fever viruses including Ebola virus by using 48 TaqMan-based PCR assays with the limit of detection for the assays ranging from 10 to 0.001 plaque-forming units / PCR.

While RT-PCR with high sensitivity and specificity have been widely used to quantify RNA viruses, RNA templates as positive controls were not always available and safe for highly infective pathogens such as SARS virus and highly pathogenic avian influenza viruses. In addition, RNA templates from killed viruses tend to degrade under the influence of RNase and metal ions. In comparison, the VLPs equipped with specific RNA fragments have been widely used as stable, reliable and safe positive controls for RT-PCR [22–24].

A generic PCR that can detect and differentiate all Ebola virus species is needed as increased international movement of people increases the potential of transmission for multiple Ebola virus species with varying pathogenicity [11, 17, 25–28]. Here we report a highly-sensitive one-step reverse-transcription FRET-PCR capable of rapidly identifying and differentiating all five Ebola virus species.

### Materials and Methods

**Plasmids containing portion of Ebola virus**

Five plasmids, each comprising the first 600 bp (5’end) of five Ebola virus species (Zaire ebolavirus, Sudan ebolavirus, Reston ebolavirus, Tai Forest ebolavirus and Bundibugyo ebolavirus), were created (GenScript, Nanjing, China) to serve as positive controls and quantitative standards in this study. The nucleotide fragments were synthesized and inserted into the pUC57 cloning vector, and the resulting plasmids were linearized with Sac I (Takara Biotechnology, Dalian, China) and quantified using the PicoGreen DNA fluorescence assay (Molecular Probes, Eugene, OR, USA) for preparation of quantitative standards ($10^4$, $10^3$, $10^2$, $10^1$, $10^0$ copies /10 μl).

**Preparation of Ebola virus RNA transcripts**

Since it is not allowed to use viable Ebola virus for research in China and none of five Ebola virus species was available to us, transcripts made from the plasmids described above and virus-like-particles (VLPs) containing Ebola virus RNA fragment were used as positive controls. The transcription reaction was run with MEGAscript Kit (Ambion by life technologies, Carlsbad, CA, USA) according to the manufacturer’s instructions. After incubation at 37°C for 4h, the transcribed products were treated with TURBO DNase (Ambion by life technologies, California, USA), followed by precipitation with lithium chloride. Finally, the yield of RNA transcripts...
was determined with the Quant-iT RiboGreen RNA Kit (Molecular Probes, Eugene, OR, USA) for preparation of the RNA standards (10⁵, 10⁴, 10³, 10², 10¹ copies /10μl).

Construction and expression of virus-like particles (VLPs) containing *Ebolaviruss* NP RNA

In addition to the positive controls of plasmids and transcripts described above, we prepared also the VLPs containing the *Ebolaviruss* NP RNA fragment to further verify the specificity and reverse-transcription efficiency of the established PCR in this study. The MS2 VLPs containing the NP RNA fragments of each of these five *Ebolaviruss* species were prepared as the method described by Drosten *et al.* [29]. The primers (forward primer: 5’-ATGAATTCTCCTGCTCA ACTTCTGTG-3’; reverse primer: 5’-GCAAAGCTGTAGTACTAGATGCAGAGTT-3’) of MS2 phage (ATCC 15591-B1) assembly protein gene, coat protein gene and the fragment of *Ebolaviruss* RNA NP gene was synthesized according to their sequences from GenBank data (Gene Accession#: KC24280) and were used to amplify their cDNAs by RT-PCR. Expression vector pTrc99a (Pharmacia) and their cDNA fragments were ligated with T4 DNA ligase after digestion with restriction enzyme. The prokaryotic expression was obtained by transformation of recombinant plasmids into *E. coli* JM109. The obtained VLPs were purified and tested by quantitative analysis and RT-PCR.

Inoculation of transcribed *Ebolaviruss* RNA and VLPs in human blood

Ten μl serially diluted transcribed RNAs and VLPs (10⁹, 10⁸, 10⁷, 10⁶, 10⁵ copies/10 μl) were thoroughly mixed with 50 μl human whole blood (collected in EDTA) and 150 μl 1× PBS for RNA extraction (High Pure RNA Isolation Kit, Roche, Mannheim, Germany). After vortexing for 15s with Lysis/-Binding Buffer and Red Cell Lysis Buffer (Roche Diagnostics GmbH, Mannheim, Germany), the blood samples were transferred to the High Pure filter tube and RNA eluted with 60 μl elution buffer which was stored at -80°C until thawed at room temperature for RT-PCR.

One-step FRET RT-PCR for *Ebolaviruss*

**Primers and probes.** The full genome sequences of five *Ebolaviruss* species (two representing GenBank Accession #: for Zaire ebolavirus NC_002549, KC24280; Sudan ebolavirus NC_006432, KC54539; Reston ebolavirus NC_004161, JX477166; Tai Forest ebolavirus NC_014372, FJ217162; Bundibugyo ebolavirus NC_014373, KC545396), and those two monophyletic genus (*Marburgvirus* KC545388, NC_001608; *Cuevavirus* JF828358, NC_016144) were obtained from GenBank (Fig 1). Based on the conserved and variable regions determined by Clustal Multiple Alignment, we identified highly conserved regions in 1–146 bp of the genome which were common to all five *Ebolaviruss* species and used for the forward primer, 6-FAM probe and LCRRed 640 probe (Fig 1, Table 1). The regions between 146 bp and 255 bp were highly conserved for individual *Ebolaviruss* species but were highly variable among the different species and were thus used to design five reverse primers to specifically amplify only a single *Ebolaviruss* species (Fig 1, Table 1). The primers and probes demonstrated high level of mismatches with *Cuevavirus* (35–40 mismatches) and *Marburgvirus* (no corresponding fragment).

**Thermal cycling.** One-step RT-PCR was performed in a LightCycler 480 II real-time PCR platform. Each reaction was performed in a 20μl final volume containing 10μl of plasmid DNA, transcribed RNA or VLPs and 10μl master mix with a final concentration of 1μM forward primer, 0.2μM 6-FAM probe, 0.2μM LCRRed 640 probe, 1μM Reston ebolavirus reverse primer and 0.5μM reverse primers for the four other *Ebolaviruss* species (Table 1). For each sample in 20μl reaction, 0.14 U SuperScript III reverse transcriptase (Invitrogen) was added
One-Step RT-PCR for Differential Detection of Five Ebola Virus Species

and other reaction components were used as described [30]. Thermal cycling consisted of one reverse transcription step, 18 high-stringency step-down cycles and 30 relaxed-stringency fluorescence acquisition cycles. The reverse transcription step was at 55°C for 15 min, followed by denaturation at 95°C for 2 min. The 18 high-stringency step-down thermal cycles were 6×1 sec @ 95°C, 12 sec @ 70°C, 8 sec @ 72°C; 9×1 sec @ 95°C, 12 sec @ 68°C, 8 sec @ 72°C; 3×1 sec @ 95°C, 12 sec @ 66°C, 8 sec @ 72°C. The relaxed-stringency fluorescence acquisition cycling consisted of 30×1 sec @ 95°C, 8 sec @ 52°C, 30 sec @ 67°C and 30 sec @ 72°C.

Table 1. Primers and probes used in this study.

| Primer/probe       | Sequence (5’–3’)                  | Location | Note                   |
|--------------------|-----------------------------------|----------|------------------------|
| Forward primer     | CGGACACAACAAAAAGAAGAAG–3’         | 1–22     | Common to all Ebola virus species |
| 6-FAM probe        | 6-FAM– TAGTTATGCGACACACAWRRK–phos | 33–54    |                        |
| LCRRed probe       | GAGGAAATATTTTAACTTCTCC–LCRed640   | 56–78    |                        |
| Reverse primer-1   | GCCAATCTCAGTTTGTGATT              | 125–146  | Specific for Bundibugyo |
| Reverse primer-2   | GGAATGGGGTGACATCTGACAAAA          | 146–166  | Specific for Tai Forest |
| Reverse primer-3   | CATGTTATGCGAATTTTGTGTG          | 169–192  | Specific for Reston    |
| Reverse primer-4   | AAAGCCACACTGACACCGCC             | 192–211  | Specific for Sudan     |
| Reverse primer-5   | GAACCTTTGATGATGATGACCTTA         | 232–255  | Specific for Zaire     |

doi:10.1371/journal.pone.0126281.t001

doi:10.1371/journal.pone.0126281.g001

Fig 1. Alignment of primers and probes for five Ebola virus species. Nucleotide sequences of the primers (one forward primer and five reverse primers for all Ebola virus species) and probes are shown at the top of the frames while the corresponding nucleotide sequences of five species of Ebola virus are shown at the bottom. Dots indicated that nucleotides are identical to those of primers/probes, and strips indicated deletion of nucleotides. The upstream primer was used as shown while the downstream primers and probes were used as reverse oligonucleotides. The 6-FAM and LCRRed-640 probes had 5 and 1 degenerate nucleotides, respectively. The numbers associated with primers/probes indicate the positions of primers/probes in the whole genome of Ebola virus.

doi:10.1371/journal.pone.0126281.g001
High-resolution melting genotyping analysis.  After the FRET-PCR was completed, the melting curve analysis for probes annealing to the PCR products was determined by monitoring the fluorescence from 38°C to 85°C as described previously [30, 31]. Data were analyzed as 640 nm: 530 nm (F4/F1) fluorescence ratios, and the first derivative of F4/F1 (-d(F4/F1)/dt) was evaluated (Fig 2).

Specificity of the one-step RT FRET-PCR.  The BLASTN with the organism options of including and excluding Ebolavirus (taxid: 186536) was performed on each of the primers and probes to verify the specificity of the designed oligonucleotides we designed. Specificity of the one-step RT FRET-PCR was also evaluated by synthesizing each of five plasmids containing portions of each Ebolavirus species (Zaire ebolavirus, Sudan ebolavirus, Reston ebolavirus Taï Forest ebolavirus and Bundibugyo ebolavirus), and a mixture of the five plasmids (Fig 3). In addition, the following oligonucleotide polymers were synthesized (GenScript, Nanjing, China) to further test the sensitivity of the established PCR: 1) the first 100 bp of the PCR amplicon for EVD Zaire (contains forward primer and two probes); 2) the complimentary sequences of the first 100 bp of the PCR amplicon for EVD Zaire; 3) the 33–250 bp of the the PCR amplicon for EVD Zaire (contains two probes and five downstream primers).

The specificity of the established PCR in this work was further tested on the nucleic acids of other pathogens causing hemorrhagic fever or similar clinical signs as Ebolavirus (Bunyavirus, Japanese encephalitis virus, Cuevavirus, Dengue virus, Yellow fever virus, Hanta virus, forest encephalitis virus, Lassa fever virus, Marburg virus), Nucleic acids of these viruses were provided by the National Institute for Food and Drug Control, China Food and Drug Administration). The PCR products from the reactions with the plasmids of the individual Ebolavirus species and the mixture containing them all, were verified by electrophoresis through a 4%
agarose gel (BIOWEST, Hong Kong, China) at 90 v for 90 min and stained with SYBR Safe DNA Gel Stain (Invitrogen, Carlsbad, USA) (Fig 4). A high concentration (4%) of BIOWEST Gel (gel strength ≥750, gelling range around 36–39°C, and melting range around 87–89°C) ensures efficient differentiation of the small sizes of PCR fragments in this study.

Sensitivity of the one-step RT FRET-PCR. The sensitivity was determined using serially diluted plasmids (10^4, 10^3, 10^2, 10^1, 10^0 /10μl) containing sequences of Zaire ebolavirus (A), Sudan ebolavirus (B), Reston ebolavirus (C), Tai Forest ebolavirus (D), Bundibugyo ebolavirus (E) and negative control were detected by the one-step reverse transcription FRET-PCR established in this study. The detection sensitivity was one copy per reaction system.

doi:10.1371/journal.pone.0126281.g003

Fig 3. PCR amplification curves of serially diluted plasmids containing each of five Ebolavirus species. The plasmid quantitative standards (10^4, 10^3, 10^2, 10^1, 10^0 /10μl) containing sequences of Zaire ebolavirus (A), Sudan ebolavirus (B), Reston ebolavirus (C), Tai Forest ebolavirus (D), Bundibugyo ebolavirus (E) and negative control were detected by the one-step reverse transcription FRET-PCR established in this study. The detection sensitivity was one copy per reaction system.

Sensitivity of the one-step RT FRET-PCR. The sensitivity was determined using serially diluted plasmids (10^4, 10^3, 10^2, 10^1, 10^0 copies of DNA/ 10 μl), transcribed Ebolavirus RNAs (10^5, 10^4, 10^3, 10^2, 10^1, 10^0 copies of RNA/ 10 μl) and Ebolavirus RNA-containing VLPs (10^5, 10^4, 10^3, 10^2, 10^1, 10^0 copies of RNA/ 10 μl). Also, human whole blood spiked with transcribed RNAs (10^6, 10^5, 10^4, 10^3, 10^2, 10^1 copies of RNA/tube with 50 μl whole blood) was amplified to determine the detection limit of the established one-step RT-PCR that could be expected with clinical samples.
Results and Discussion

Our one-step RT FRET-PCR was capable of detecting a single DNA copy and 10 RNA copies of all five *Ebolavirus* species (Figs 3 and 5). When whole blood spiked with transcribed *Ebolavirus* RNA and VLPs were tested, the detection limit was 100 copies of RNA per PCR reaction (Fig 5), equivalent to 320 copies of *Ebolavirus* in 1 ml whole blood. Triplicates were performed for each assay. The BLASTN results for each of the 8 oligonucleotides we used in the one-step RT FRET-PCR showed they were specific for the *Ebolavirus* species and did not cross-react with partial amplicons or other viruses in the family *Filoviridae*. No PCR amplification was observed with nucleic acids of eight types of pathogens which induce hemorrhagic fever or similar clinical signs as *Ebolavirus*.

Due to the different levels of mismatches between the probes we designed and the PCR amplicons we generated from the different *Ebolavirus* species (Fig 1), melting curve analysis of the PCRs products showed unique and distinct *T<sub>m</sub>* for each of the five *Ebolavirus* species (Fig 2): *Zaire*: flat dual peaks between 53.0°C and 56.9°C; *Sudan*: 51.6°C; *Reston*: flat dual peaks between 47.5°C and 54.9°C; *Taï Forest*: 52.8°C; *Bundibugyo*: dual peaks at 48.9°C and 53.5°C. The temperatures and shapes of the melting curves were consistent even with changes in the concentrations of *Ebolavirus* used in the reaction (Fig 2). Furthermore, the specific reverse primers we designed gave amplicons of different sizes for each of the five *Ebolavirus* species (*Zaire ebolavirus* 255bp; *Sudan ebolavirus* 211bp; *Reston ebolavirus* 192bp; *Taï Forest ebolavirus* 166bp; *Bundibugyo ebolavirus* 146bp) (Fig 4). The detection sensitivity, melting temperatures and amplicon sizes of each of these five *Ebolavirus* species were confirmed when the established RT-PCR was applied on *Ebolavirus* NP RNA-containing VLPs (Fig 6).

In the one-step RT-PCR established in this study, the combination of a single set of forward primer and probes with five different reverse primers gave very high sensitivity and differential
ability. While the system detects all five *Ebolavirus* with highly sensitivity (1 copy of DNA, 10 copies of RNA, or 320 copies of RNA / 1 ml whole blood), the unique $T_m$ distribution enables the convenient differentiation of the five *Ebolavirus* species (Fig 2). In laboratories that do not have real-time PCR machines and melting curve analysis, our primers can be used in standard PCRs and the five *Ebolavirus* species differentiated by the specific size of the amplicon identified for each species in gel electrophoresis (Fig 4).

Fig 5. Amplification curves of reverse-transcription PCR on transcribed *Ebolavirus* RNAs and blood samples spiked with transcribed RNA. A: The different concentrations of transcribed *Zaire ebolavirus* RNA ($10^5$, $10^4$, $10^3$, $10^2$, $10^1$, $10^0$ /10 µl) were detected with the one-step reverse transcription FRET-PCR described in this study, and the detection limitation was 10 copies per reaction system. B: Serial concentrations of transcribed *Zaire ebolavirus* RNAs ($10^6$, $10^5$, $10^4$, $10^3$, $10^2$, $10^1$, $10^0$ /10 µl) were spiked into human whole blood and were extracted with RNA purification kit, followed by the one-step reverse transcription FRET-PCR established in this study. The detection limitation was 100 RNA copies per reaction, equivalent to 320 copies of *Zaire Ebolavirus* in 1 ml whole blood. Triplicates (A) or duplicates (B) were performed for each concentration of tested *Ebolavirus* RNA.

doi:10.1371/journal.pone.0126281.g005
Fig 6. The sensitivity, melting curve analysis and gel electrophoresis of the one-step RT-FRET-PCR performed on Ebolavirus RNA-containing VLPs. The amplification curves of 100 copies of VLPs containing each of these five Ebolavirus species were run in the RT FRET PCR established in this study (A), followed by melting curves analysis (B) and gel electrophoresis (C). The Amplification curves of reverse-transcription PCR on serially diluted VLPs inoculated in blood sample showed similar sensitivity as in blood samples spiked with transcribed RNA (data not shown).

doi:10.1371/journal.pone.0126281.g006
While RNA templates as positive controls were not always available and safe for highly infective pathogens such as SARS virus and highly pathogenic avian influenza viruses, the VLPs equipped with specific RNA fragments have been widely used as stable, reliable and safe positive controls for RT-PCR [22–24]. The VLPs containing *Ebolavirus* NP RNA established in this work are adopted as standards to evaluate and certify *Ebolavirus*-related commercial diagnostic kits by National Institute for Food and Drug Control, Food and Drug Administration of China.

While simple PCR tends to provide high sensitivity but lacks ability to differentiate multiple targets simultaneously, multiplex PCR has the capacity to detect and differentiate multiple targets but tends to have a reduced sensitivity. Our study has established a novel highly-sensitive one-step RT FRET-PCR with one set of upstream primer/probes and five downstream primers that can rapidly identify and differentiate all five *Ebolavirus* species.

**Author Contributions**

Conceived and designed the experiments: CW GL JZ. Performed the experiments: GL JZ CZ XL DS ZY. Analyzed the data: CW GL JZ. Contributed reagents/materials/analysis tools: CW GL JZ. Wrote the paper: CW JZ. Designed the software used in analysis: CW JZ.

**References**

1. Ross AG, Olveda RM, Li YS. Are we ready for a global pandemic of Ebola virus? Int J Infect Dis. 2014; 28: 217–218. doi: 10.1016/j.ijid.2014.09.001 PMID: 25403915

2. Kuhn JH, Bao Y, Bavari S, Becker S, Bradfute S, Brauburger K, et al. Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNA. Arch Virol. 2014; 159: 1229–1237. doi: 10.1007/s00705-013-1877-2 PMID: 24190508

3. Barrette RW, Metwally SA, Rowland JM, Xu L, Zaki SR, Nichol ST, et al. Discovery of swine as a host for the *Reston ebolavirus*. Science. 2009; 325: 204–206. doi: 10.1126/science.1172705 PMID: 19590002

4. Hartman AL, Towner JS, Nichol ST. Ebola and Marburg hemorrhagic fever. Clin Lab Med. 2010; 30: 161–177. doi: 10.1016/j.cll.2009.12.001 PMID: 20513546

5. Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet. 2011; 377: 849–862. doi: 10.1016/ S0140-6736(10)61079-6 PMID: 21084112

6. Carroll SA, Towner JS, Sealy TK, McMullan LK, Kristovka ML, Burt FJ, et al. Molecular evolution of viruses of the family *Filoviridae* based on 97 whole-genome sequences. J Virol. 2013; 87: 2608–2616. doi: 10.1128/JVI.03118-12 PMID: 23255795

7. Johnson KM, Lange JV, Webb PA, Murphy FA. Isolation and partial characterisation of a new virus causing acute haemorrhagic fever in Zaire. Lancet. 1977; 1: 569–571. PMID: 65661

8. Heymann DL, Weisfeld JS, Webb PA, Johnson KM, Cairns T, Berquist H. Ebola hemorrhagic fever: Tandala, Zaire, 1977–1978. J Infect Dis. 1980; 142: 372–376. PMID: 7441008

9. Le Guenno B, Formenty P, Wyers M, Gounon P, Walker F, Boesch C. Isolation and partial characterisation of a new strain of Ebola virus. Lancet. 1995; 345: 1271–1274. PMID: 7746057

10. Towner JS, Sealy TK, Kristovka ML, Albarino CG, Conlan S, Reeder SA, et al. Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog. 2008; 4:e1000212. doi: 10.1371/journal.ppat.1000212 PMID: 19023410

11. Pigott DM, Golding N, Mylne A, Huang Z, Henry AJ, Weiss DJ, et al. Mapping the zoonotic niche of *Ebola virus* disease in Africa. Elife. 2014; 3: e04395. doi: 10.7554/eLife.04395 PMID: 25201877

12. World Health Organization. *Ebola* Current Situation, data up to 25 January 2015. Available: http://apps.who.int/ebola/en/current-situation.

13. Towner JS, Rollin PE, Bausch DG, Sanchez A, Crary SM, Vincent M, et al. Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. J Virol. 2004; 78: 4330–4341. PMID: 15047846

14. Huang Y, Wei H, Wang Y, Shi Z, Raoul H, Yuan Z. Rapid detection of filoviruses by real-time TaqMan polymerase chain reaction assays. Virol Sin. 2012; 27: 273–277. doi: 10.1007/s12250-012-0252-y PMID: 23001480

15. Ogawa H, Miyamoto H, Ebihara H, Ito K, Morikawa S, Feldmann H, et al. Detection of all known filovirus species by reverse transcription-polymerase chain reaction using a primer set specific for the viral
nucleoprotein gene. J Virol Methods. 2010; 171: 310–313. doi: 10.1016/j.jviromet.2010.11.010 PMID: 21093485

16. Liu Y, Shi ZX, Ma YK, Wang HT, Wang ZY, Shao DH, et al. Development of SYBR Green I real-time RT-PCR for the detection of Ebola virus. Bing Du Xue Bao. 2012; 28: 567–571. PMID: 2333935

17. Fajfr M, Neubauerova V, Pajer P, Kubickova P, Ruzek D. Detection panel for identification of twelve hemorrhagic viruses using real-time RT-PCR. Epidemiol Mikrobiol Imunol. 2014; 63: 238–244. PMID: 25412490

18. Gibb TR, Norwood DA Jr, Woollen N, Henchal EA. Development and evaluation of a fluorogenic 5' nuclease assay to detect and differentiate between Ebola virus subtypes Zaire and Sudan. J Clin Microbiol. 2001; 39: 4125–4130. PMID: 11682540

19. Panning M, Laue T, Olschlager S, Eickmann M, Becker S, Raith S, et al. Diagnostic reverse-transcription polymerase chain reaction kit for filoviruses based on the strain collections of all European biosafety level 4 laboratories. J Infect Dis. 2007; 196(Suppl 2): S199–204. PMID: 17940950

20. Trombley AR, Wachter L, Garrison J, Buckley-Beason VA, Jahrling J, Hensley LE, et al. Comprehensive panel of real-time TaqMan polymerase chain reaction assays for detection and absolute quantification of filoviruses, arenaviruses, and New World hantaviruses. Am J Trop Med Hyg. 2010; 82: 954–960. doi: 10.4269/ajtmh.2010.09-0636 PMID: 20439981

21. Yang Y, Bai L, Hu KK, Yang ZH, Hu JP, Wang J. Multiplex real-time PCR method for rapid detection of Marburg virus and Ebola virus. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2012; 26: 313–315. PMID: 23189855

22. Chen XS, Garcea RL, Goldberg I, Casini G, Harrison SC. Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell. 2000; 5: 557–567. PMID: 10882140

23. Joshi SM, Vogt VM. Role of the Rous sarcoma virus p10 domain in shape determination of gag virus-like particles assembled in vitro and within Escherichia coli. J Virol. 2000; 74: 10260–10268. PMID: 11024160

24. Xiang J, Wünschmann S, George SL, Klünzmann D, Schmidt WN, LaBrecque DR, et al. Recombinant hepatitis C virus-like particles expressed by Baculovirus: utility in cell-binding and antibody detection assays. J Med Virol. 2002; 68: 537–543. PMID: 12376962

25. Bhaumik S. Twin Ebola outbreaks in Africa: Uganda and Democratic Republic of Congo affected. Natl Med J India. 2012; 25: 317. PMID: 23448651

26. Goeijenbier M, van Kampen JJ, Reusken CB, Koopmans MP, van Gorp EC. Ebola virus disease: a review on epidemiology, symptoms, treatment and pathogenesis. Neth J Med. 2014; 72: 442–448. PMID: 25387613

27. Li YH, Chen SP. Evolutionary history of Ebola virus. Epidemiol Infect.http://www.ncbi.nlm.nih.gov/pubmed/24040779 2014; 142: 1138–1145. doi: 10.1017/S0950268813002215 PMID: 24040779

28. Burd EM. Ebola Virus: a Clear and Present Danger. J Clin Microbiol. 2015; 53: 4–8. doi: 10.1128/JCM.03115-14 PMID: 25392362

29. Drosten C, Seifried E, Roth WK. TaqMan 5'-nuclease human immunodeficiency virus type 1 PCR assay with phage-packaged competitive internal control for high-throughput blood donor screening. J Clin Microbiol. 2001; 39: 4302–4308. PMID: 11724836

30. Wang C, Ahluwalia SK, Li Y, Gao D, Poudel A, Chowdhury E, et al. Frequency and therapy monitoring of canine Babesia spp. infection by high-resolution melting curve quantitative FRET-PCR. Vet Parasitol. 2010; 168: 11–18. doi: 10.1016/j.vetpar.2009.10.015 PMID: 19931290

31. Kelly PJ, Xu C, Lucas H, Loftis A, Abete J, Zeoli F, et al. Ehrlichiosis, babesiosis, anaplasmosis and hepatozoonosis in dogs from St Kitts, West Indies. PLoS One 2013; 8: e53450. doi: 10.1371/journal. pone.0053450 PMID: 23335965